Investigating a new drug to slow down Alzheimer's disease progression
Official title: First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers
Funded at Oligomerix, INC · NIH-10673633 · Data updated 2026-11-12
This study is testing a new drug called OLX-07010 to see if it can help slow down Alzheimer's disease by targeting early changes in the brain, and it's looking for healthy volunteers to help find out if the drug is safe and effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oligomerix, INC NIH-funded |
| Lab location | 1 site (White Plains, UNITED STATES) |
| Project start | August 1, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $2,039,616 |
| NIH project number | 5R01AG076565-02 |
| Project ID | NIH-10673633 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are healthy adults aged 21 and older who are interested in contributing to Alzheimer's disease research.
✕Less likely to help
Patients currently diagnosed with Alzheimer's disease or those with significant cognitive impairment may not benefit from this research.
What this research studies
This research focuses on developing a new small molecule drug, OLX-07010, aimed at modifying the progression of Alzheimer's disease (AD). The study will involve healthy volunteers to assess the safety and effectiveness of this drug, which targets the early stages of tau protein aggregation, a key factor in AD. Participants will undergo various assessments to evaluate how well the drug works in preventing the formation of harmful tau aggregates. The ultimate goal is to provide a new therapeutic option for the millions affected by Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that slows the progression of Alzheimer's disease, improving quality of life for patients and their families.
How similar studies have gone: While there have been various approaches to treating Alzheimer's, this specific method targeting tau self-association is relatively novel and has not been extensively tested in human trials.
Where this research is happening
-
Oligomerix, INC
White Plains, United States Active
Researchers
- Principal investigator: Erhardt, William a. — Oligomerix, INC
- Study coordinator: Erhardt, William a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.